Cells from discarded dressings differentiate chronic from acute wounds in patients with Epidermolysis Bullosa.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 09 2020
Historique:
received: 14 05 2020
accepted: 22 07 2020
entrez: 16 9 2020
pubmed: 17 9 2020
medline: 15 12 2020
Statut: epublish

Résumé

Impaired wound healing complicates a wide range of diseases and represents a major cost to healthcare systems. Here we describe the use of discarded wound dressings as a novel, cost effective, accessible, and non-invasive method of isolating viable human cells present at the site of skin wounds. By analyzing 133 discarded wound dressings from 51 patients with the inherited skin-blistering disease epidermolysis bullosa (EB), we show that large numbers of cells, often in excess of 100 million per day, continually infiltrate wound dressings. We show, that the method is able to differentiate chronic from acute wounds, identifying significant increases in granulocytes in chronic wounds, and we show that patients with the junctional form of EB have significantly more cells infiltrating their wounds compared with patients with recessive dystrophic EB. Finally, we identify subsets of granulocytes and T lymphocytes present in all wounds paving the way for single cell profiling of innate and adaptive immune cells with relevance to wound pathologies. In summary, our study delineates findings in EB that have potential relevance for all chronic wounds, and presents a method of cellular isolation that has wide reaching clinical application.

Identifiants

pubmed: 32934247
doi: 10.1038/s41598-020-71794-1
pii: 10.1038/s41598-020-71794-1
pmc: PMC7492213
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15064

Références

Sen, C. K. et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 17, 763–771 (2009).
pubmed: 19903300 pmcid: 2810192 doi: 10.1111/j.1524-475X.2009.00543.x
Duarte, A. A., Mohsin, S. & Golubnitschaja, O. Diabetes care in figures: current pitfalls and future scenario. EPMA J. 9, 125–131 (2018).
pubmed: 29896313 pmcid: 5972141 doi: 10.1007/s13167-018-0133-y
Bloom, D. E. et al. Macroeconomic implications of population ageing and selected policy responses. Lancet 385, 649–657 (2015).
pubmed: 25468167 doi: 10.1016/S0140-6736(14)61464-1
Popkin, B. M., Adair, L. S. & Ng, S. W. Global nutrition transition and the pandemic of obesity in developing countries. Nutr. Rev. 70, 3–21 (2012).
pubmed: 22221213 pmcid: 3257829 doi: 10.1111/j.1753-4887.2011.00456.x
Armstrong, D. G., Wrobel, J. & Robbins, J. M. Guest Editorial: are diabetes-related wounds and amputations worse than cancer?. Int. Wound J. 4, 286–287 (2007).
pubmed: 18154621 doi: 10.1111/j.1742-481X.2007.00392.x
Frykberg, R. G. & Banks, J. Challenges in the treatment of chronic wounds. Adv. Wound Care (New Rochelle) 4, 560–582 (2015).
doi: 10.1089/wound.2015.0635
Sorg, H., Tilkorn, D. J., Hager, S., Hauser, J. & Mirastschijski, U. Skin wound healing: an update on the current knowledge and concepts. Eur. Surg. Res. 58, 81–94 (2017).
pubmed: 27974711 doi: 10.1159/000454919
Yager, D. R. et al. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair Regen. 5, 23–32 (1997).
pubmed: 16984454 doi: 10.1046/j.1524-475X.1997.50108.x
Fivenson, D. P. et al. Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Repair Regen. 5, 310–322 (1997).
pubmed: 16984441 doi: 10.1046/j.1524-475X.1997.50405.x
Yager, D. R., Kulina, R. A. & Gilman, L. A. Wound fluids: a window into the wound environment?. Int. J. Low Extrem Wounds 6, 262–272 (2007).
pubmed: 18048872 doi: 10.1177/1534734607307035
Ellis, S., Lin, E. J. & Tartar, D. Immunology of wound healing. Curr. Dermatol. Rep. 7, 350–358 (2018).
pubmed: 30524911 pmcid: 6244748 doi: 10.1007/s13671-018-0234-9
Cox, G., Crossley, J. & Xing, Z. Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary inflammation in vivo. Am. J. Respir. Cell Mol. Biol. 12, 232–237 (1995).
pubmed: 7865221 doi: 10.1165/ajrcmb.12.2.7865221
Ashcroft, G. S., Horan, M. A. & Ferguson, M. W. Aging alters the inflammatory and endothelial cell adhesion molecule profiles during human cutaneous wound healing. Lab. Investig. 78, 47–58 (1998).
pubmed: 9461121
Goren, I. et al. A transgenic mouse model of inducible macrophage depletion: effects of diphtheria toxin-driven lysozyme M-specific cell lineage ablation on wound inflammatory, angiogenic, and contractive processes. Am. J. Pathol. 175, 132–147 (2009).
pubmed: 19528348 pmcid: 2708801 doi: 10.2353/ajpath.2009.081002
Mori, R., Kondo, T., Nishie, T., Ohshima, T. & Asano, M. Impairment of skin wound healing in beta-1,4-galactosyltransferase-deficient mice with reduced leukocyte recruitment. Am. J. Pathol. 164, 1303–1314 (2004).
pubmed: 15039218 pmcid: 1615332 doi: 10.1016/S0002-9440(10)63217-8
Dovi, J. V., He, L. K. & DiPietro, L. A. Accelerated wound closure in neutrophil-depleted mice. J. Leukoc. Biol. 73, 448–455 (2003).
pubmed: 12660219 doi: 10.1189/jlb.0802406
Tanno, H. et al. Invariant NKT cells promote skin wound healing by preventing a prolonged neutrophilic inflammatory response. Wound Repair Regen. 25, 805–815 (2017).
pubmed: 28940971 doi: 10.1111/wrr.12588
Fine, J. D. et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J. Am. Acad. Dermatol. 70, 1103–1126 (2014).
pubmed: 24690439 doi: 10.1016/j.jaad.2014.01.903
Petrof, G., Martinez-Queipo, M., Mellerio, J. E., Kemp, P. & McGrath, J. A. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br. J. Dermatol. 169, 1025–1033 (2013).
pubmed: 24032424 doi: 10.1111/bjd.12599
Vatankhah, N. et al. Predictive value of neutrophil-to-lymphocyte ratio in diabetic wound healing. J. Vasc. Surg. 65, 478–483 (2017).
pubmed: 27887858 doi: 10.1016/j.jvs.2016.08.108
Leliefeld, P. H. C. et al. Differential antibacterial control by neutrophil subsets. Blood Adv. 2, 1344–1355 (2018).
pubmed: 29895625 pmcid: 5998927 doi: 10.1182/bloodadvances.2017015578
Lane, P. J. et al. Lymphoid tissue inducer cells: bridges between the ancient innate and the modern adaptive immune systems. Mucosal Immunol. 2, 472–477 (2009).
pubmed: 19741599 doi: 10.1038/mi.2009.111
Wagner, J. E. et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. J. Med. 363, 629–639 (2010).
pubmed: 20818854 pmcid: 2967187 doi: 10.1056/NEJMoa0910501
Petrof, G. et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J. Investig. Dermatol. 135, 2319–2321 (2015).
pubmed: 25905587 doi: 10.1038/jid.2015.158
Itoh, M., Kiuru, M., Cairo, M. S. & Christiano, A. M. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc. Natl. Acad. Sci. U.S.A. 108, 8797–8802 (2011).
pubmed: 21555586 pmcid: 3102348 doi: 10.1073/pnas.1100332108
Nystrom, A. et al. Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa. Proc. Natl. Acad. Sci. U.S.A. 115, E705–E714 (2018).
pubmed: 29305555 pmcid: 5789908 doi: 10.1073/pnas.1709111115
Christoffersson, G. & Phillipson, M. The neutrophil: One cell on many missions or many cells with different agendas?. Cell Tissue Res. 371, 415–423 (2018).
pubmed: 29435651 pmcid: 5820408 doi: 10.1007/s00441-017-2780-z
Fuentes, I. et al. Reduced microbial diversity is a feature of recessive dystrophic epidermolysis bullosa-involved skin and wounds. J. Investig. Dermatol. 138, 2492–2495 (2018).
pubmed: 29753707 doi: 10.1016/j.jid.2018.04.026
Tyring, S. K., Chopra, V., Johnson, L. & Fine, J. D. Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. Arch. Dermatol. 125, 797–800 (1989).
pubmed: 2730100 doi: 10.1001/archderm.1989.01670180069008
Chopra, V., Tyring, S. K., Johnson, L. & Fine, J. D. Peripheral blood mononuclear cell subsets in patients with severe inherited forms of epidermolysis bullosa. Arch. Dermatol. 128, 201–209 (1992).
pubmed: 1739298 doi: 10.1001/archderm.1992.01680120073006
Bakshi, S. S. Regarding “predictive value of neutrophil-to-lymphocyte ratio in diabetic wound healing”. J. Vasc. Surg. 66, 1915 (2017).
pubmed: 29169549 doi: 10.1016/j.jvs.2017.07.128

Auteurs

Ignacia Fuentes (I)

DEBRA Chile, Francisco de Villagra 392, Ñuñoa, Santiago, Chile. Ignacia.fuentesbustos@gmail.com.
Centro de Genética Y Genómica, Facultad de Medicina Clínica Alemana, Universidad de Desarrollo, Santiago, Chile. Ignacia.fuentesbustos@gmail.com.

Christina Guttmann-Gruber (C)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria.

Birgit Tockner (B)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria.

Anja Diem (A)

EB House Austria, Outpatient Unit, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria.

Alfred Klausegger (A)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria.

Glenda Cofré-Araneda (G)

DEBRA Chile, Francisco de Villagra 392, Ñuñoa, Santiago, Chile.

Olga Figuera (O)

DEBRA Chile, Francisco de Villagra 392, Ñuñoa, Santiago, Chile.

Yessia Hidalgo (Y)

Consorcio Regenero, Chilean Consortium for Regenerative Medicine, 7620157, Santiago, Chile.
Cells for Cells, 7620157, Santiago, Chile.
Faculty of Medicine, Universidad de Los Andes, 7620001, Santiago, Las Condes, Chile.

Pilar Morandé (P)

DEBRA Chile, Francisco de Villagra 392, Ñuñoa, Santiago, Chile.

Francis Palisson (F)

DEBRA Chile, Francisco de Villagra 392, Ñuñoa, Santiago, Chile.
Facultad de Medicina Clínica Alemana, Universidad de Desarrollo, Santiago, Chile.

Boris Rebolledo-Jaramillo (B)

Centro de Genética Y Genómica, Facultad de Medicina Clínica Alemana, Universidad de Desarrollo, Santiago, Chile.

María Joao Yubero (MJ)

DEBRA Chile, Francisco de Villagra 392, Ñuñoa, Santiago, Chile.
Facultad de Medicina Clínica Alemana, Universidad de Desarrollo, Santiago, Chile.

Raymond J Cho (RJ)

UCSF Dermatology, San Francisco, CA, USA.

Heather I Rishel (HI)

Dermatology Department, Stanford University School of Medicine, Stanford, CA, USA.

M Peter Marinkovich (MP)

Dermatology Department, Stanford University School of Medicine, Stanford, CA, USA.
Dermatology Service, VA Medical Center, Palo Alto, CA, USA.

Joyce M C Teng (JMC)

Dermatology Department, Stanford University School of Medicine, Stanford, CA, USA.

Timothy G Webster (TG)

Dermatology and Cutaneous Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Room 406, 233 South Tenth Street, Philadelphia, PA, 19107, USA.

Marco Prisco (M)

Dermatology and Cutaneous Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Room 406, 233 South Tenth Street, Philadelphia, PA, 19107, USA.

Luis H Eraso (LH)

Vascular Medicine, Thomas Jefferson University, Philadelphia, PA, USA.

Josefina Piñon Hofbauer (J)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria.

Andrew P South (AP)

Dermatology and Cutaneous Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Room 406, 233 South Tenth Street, Philadelphia, PA, 19107, USA. andrew.south@jefferson.edu.
Joel and Joan Center for Fibrotic Diseases Research, Thomas Jefferson University, Philadelphia, PA, USA. andrew.south@jefferson.edu.
Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. andrew.south@jefferson.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH